scholarly journals Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer

2013 ◽  
Vol 16 (2) ◽  
pp. 132-138 ◽  
Author(s):  
G Schaefer ◽  
J-M Mosquera ◽  
R Ramoner ◽  
K Park ◽  
A Romanel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Young Age ◽  
Erg Rearrangement

427 Correlation between ERG rearrangement and PTEN loss with capsular penetration in prostate cancer

2012 ◽  
Vol 11 (1) ◽  
pp. e427-e427a
Author(s):  
L. Brosh ◽  
E. Abril ◽  
C. Cortez ◽  
A. Algotar ◽  
W. Meek ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pten Loss ◽  
Erg Rearrangement

scholarly journals ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer

Urology ◽  
2010 ◽  
Vol 75 (4) ◽  
pp. 762-767 ◽  
Author(s):  
Sven Perner ◽  
Maria A. Svensson ◽  
Ruhella R. Hossain ◽  
John R. Day ◽  
Jack Groskopf ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Locally Advanced Prostate Cancer ◽  
Metastasis Patterns ◽  
Erg Rearrangement

scholarly journals Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer

Neoplasia ◽  
2010 ◽  
Vol 12 (7) ◽  
pp. 590-IN21 ◽  
Author(s):  
Kyung Park ◽  
Scott A. Tomlins ◽  
Kumaran M. Mudaliar ◽  
Ya-Lin Chiu ◽  
Raquel Esgueva ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Erg Rearrangement

Automated quantum dots ISH assay for detection of ERG rearrangement and PTEN deletion in prostate cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5045-5045
Author(s):  
Lei Tang ◽  
Wenjun Zhang ◽  
Antony Hubbard ◽  
Patrick S Brunhoeber ◽  
Yixin Wang
Keyword(s):  
Prostate Cancer ◽  
Quantum Dots ◽  
Emission Spectra ◽  
Pten Gene ◽  
Unfavorable Clinical Outcome ◽  
Pten Deletion ◽  
Prostate Cancers ◽  
Photo Stability ◽  
In Situ Detection ◽  
Erg Rearrangement

5045 Background: ERG rearrangement and PTEN deletion are the two most common genomic events in prostate cancer. Overexpression of the ERG protein caused by rearrangement of the ERG gene has been frequently associated with more aggressive prostate cancers and a poor prognosis. PTEN genomic deletion and absence of PTEN expression are associated with unfavorable clinical outcome. To detect ERG rearrangement and PTEN deletion simultaneously, we developed a four-color multiplex ISH assay using non-organic quantum dots (QD). The photo-stability and narrow emission spectra of QDs makes them desirable for ultrasensitive and multiplexing ISH applications. The automated QD ISH assay allows adequate delivery of QDs to nuclear targets and reproducible detection of ERG and PTEN gene targets. Methods: DNA probes specific for ERG 5’, ERG 3’, PTEN and CEN 10 were labeled with different haptens, digoxigenin (DIG), dinitrophenyl (DNP), thiazole sulfonamide (TS), or nitropyrazole (NP). QDs with 565, 655, 605 and 525nm wavelengths were conjugated to the anti- DIG, DNP, TS or NP antibodies, respectively. The multiplex QD ISH assay was fully automated on the VENTANA BenchMark ULTRA. FFPE prostate tissue slides were hybridized with the labeled probes. The probes were then detected by the QD-conjugated antibodies and visualized under fluorescent microscope. Results: We performed the multiplex QD ISH assay on 386 slides with tissue sections from 10 prostate specimens on 13 BenchMark ULTRA instruments. The 10 cases consisted of either benign prostate tissues or prostate cancer, positive or negative for ERG rearrangement and/or PTEN deletion. 350 (91%) of the slides were successfully stained for all 4 molecular targets. The expected ERG and PTEN status were detected with high reproducibility. Conclusions: We developed an automated QD based multiplex ISH assay to simultaneously detect ERG rearrangement and PTEN deletion in prostate cancer. The assay is highly sensitive and reproducible. It enables investigation of potential clinical use of ERG and PTEN as predictive or prognostic markers. In addition, the same technology is expected to enable multiplex in situ detection of other molecular biomarkers using standard clinical specimens.

scholarly journals ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer

2014 ◽  
Vol 17 (2) ◽  
pp. 126-131 ◽  
Author(s):  
J R Gsponer ◽  
M Braun ◽  
V J Scheble ◽  
T Zellweger ◽  
A Bachmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Protein Expression ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Erg Rearrangement

IS PROSTATE CANCER AT YOUNG AGE BIOLOGICALLY MORE AGGRESSIVE THAN IN ELDERLY MEN?

2008 ◽  
Vol 179 (4S) ◽  
pp. 652-653
Author(s):  
David Pfister ◽  
Dina Sahi ◽  
David Thuer ◽  
Carsten Ohlmann ◽  
Udo Engelmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Young Age ◽  
Elderly Men

scholarly journals Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e55207 ◽  
Author(s):  
Petra Massoner ◽  
Karl G. Kugler ◽  
Karin Unterberger ◽  
Ruprecht Kuner ◽  
Laurin A. J. Mueller ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Neuropeptide Y ◽  
Transcriptional Changes ◽  
Erg Rearrangement

scholarly journals Young-age prostate cancer

2015 ◽  
Vol 68 (7) ◽  
pp. 511-515 ◽  
Author(s):  
S Hussein ◽  
S Satturwar ◽  
T Van der Kwast
Keyword(s):  
Prostate Cancer ◽  
Young Age
Sign in / Sign up

Export Citation Format

Share Document